The pharmaceutical product Eletriptan EQL Pharma was approved Monday within the framework of a decentralized procedure (a common approval procedure used when more than one country is involved). National approvals for Sweden and Denmark are expected within approximately a month.
Eletriptan EQL Pharma belongs to a group of medicines called Selective Serotonin receptor (5HT1) agonists. Eletriptan is used to treat migraine headache with or without aura in adults.
The total turnover in Sweden and Denmark is approximately 15 MSEK annually. In Denmark, there are two generic competitors on the market in addition to the original Relpax (Pfizer). Currently there is no generic competitor on the market in Sweden. EQL Pharma aims to start selling the product by Q1 2018 at the latest.
For further information, please contact:
CEO EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
This information is information which EQL Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on July 5, 2017.
EQL Pharma AB (publ) in short
EQL Pharma is specialized in developing and selling generic medicines, i.e. medines that are medically equivalent to the originals. The company currently markets nine niche generics in the Swedish and Danish markets, in addition to these, there are a significant pipeline of additional niche generics for launch in 2017 and onwards. The business is currently entirely focused on prescription drugs in the Nordic region. EQL Pharma is based in Lund, employs 7 (8) people and is listed on AktieTorget. The company conducts extensive development of generics in cooperation with leading contract manufacturers and major pharmaceutical companies in countries including India and China.